Loading
A phase 1/2 trial of Daratumumab, Dexamethasone, Pomalidomide in multiple myeloma, run by AbbVie, now recruiting.
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06953960 by AbbVie, with 325 participants planned, started 2025-07-23 and due to reach its primary completion in 2030-12. Interventions recorded: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Multiple myeloma.
Shares Pomalidomide, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/